SonoNeu sits at the edge of ultrasound neuromodulation and engineered-cell therapeutics, with sonogenetics as its core technical layer. Its current position is preclinical and consortium-led, with ARPA-H backing and translation dependent on both biological delivery and ultrasound-device development.